HK1075403A1 - Treatment of mastalgia with 4-hydroxy tamoxifen - Google Patents

Treatment of mastalgia with 4-hydroxy tamoxifen

Info

Publication number
HK1075403A1
HK1075403A1 HK05108810A HK05108810A HK1075403A1 HK 1075403 A1 HK1075403 A1 HK 1075403A1 HK 05108810 A HK05108810 A HK 05108810A HK 05108810 A HK05108810 A HK 05108810A HK 1075403 A1 HK1075403 A1 HK 1075403A1
Authority
HK
Hong Kong
Prior art keywords
mastalgia
hydroxy tamoxifen
treatment
tamoxifen
hydroxy
Prior art date
Application number
HK05108810A
Other languages
English (en)
Inventor
Bruno De Lignieres
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of HK1075403A1 publication Critical patent/HK1075403A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05108810A 2002-12-18 2005-10-05 Treatment of mastalgia with 4-hydroxy tamoxifen HK1075403A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43395902P 2002-12-18 2002-12-18
PCT/EP2003/015028 WO2004054557A2 (en) 2002-12-18 2003-12-15 Treatment of mastalgia with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
HK1075403A1 true HK1075403A1 (en) 2005-12-16

Family

ID=32595255

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108810A HK1075403A1 (en) 2002-12-18 2005-10-05 Treatment of mastalgia with 4-hydroxy tamoxifen

Country Status (16)

Country Link
US (1) US7786172B2 (el)
EP (1) EP1572178B1 (el)
JP (1) JP4938237B2 (el)
AT (1) ATE324880T1 (el)
AU (1) AU2003303033B2 (el)
CA (1) CA2509660C (el)
CY (1) CY1106131T1 (el)
DE (1) DE60305068T2 (el)
DK (1) DK1572178T3 (el)
ES (1) ES2263072T3 (el)
HK (1) HK1075403A1 (el)
MX (1) MXPA05006526A (el)
NZ (1) NZ540494A (el)
PT (1) PT1572178E (el)
SI (1) SI1572178T1 (el)
WO (1) WO2004054557A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
AU2003294973B2 (en) 2002-12-18 2010-05-13 Besins Healthcare Luxembourg Sarl Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
CA2528431C (en) * 2003-06-09 2012-09-18 Northwestern University Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PT1748770E (pt) * 2004-03-22 2008-07-16 Besins Int Lab Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
ATE415156T1 (de) * 2004-10-14 2008-12-15 Besins Int Lab 4-hydroxytamoxifengel-formulierungen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
AU2010264524B2 (en) 2009-06-22 2015-03-19 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
MX2020002649A (es) 2017-09-11 2020-09-25 Atossa Therapeutics Inc Metodos para hacer y usar endoxifeno.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (el) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
IL120268A0 (en) 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6548491B2 (en) * 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6013270A (en) 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ES2239057T3 (es) * 1999-12-16 2005-09-16 Dermatrends, Inc. Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea.
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
PT1210951E (pt) 2000-11-30 2005-04-29 Pfizer Prod Inc Composicao que contem agonistas/antagonistas de estrogeneo e testosterona para tartamento de um declinio do nivel da hormona testosterona
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
ES2330188T3 (es) 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
AU2003294973B2 (en) 2002-12-18 2010-05-13 Besins Healthcare Luxembourg Sarl Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
CA2528431C (en) 2003-06-09 2012-09-18 Northwestern University Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
CA2509660A1 (en) 2004-07-01
AU2003303033B2 (en) 2009-06-04
ES2263072T3 (es) 2006-12-01
AU2003303033A1 (en) 2004-07-09
DE60305068T2 (de) 2007-01-11
NZ540494A (en) 2007-05-31
CA2509660C (en) 2011-08-30
CY1106131T1 (el) 2011-06-08
ATE324880T1 (de) 2006-06-15
MXPA05006526A (es) 2006-02-17
WO2004054557A3 (en) 2004-08-05
DE60305068D1 (de) 2006-06-08
DK1572178T3 (da) 2006-09-11
JP2006514949A (ja) 2006-05-18
EP1572178B1 (en) 2006-05-03
US7786172B2 (en) 2010-08-31
SI1572178T1 (sl) 2006-10-31
JP4938237B2 (ja) 2012-05-23
EP1572178A2 (en) 2005-09-14
PT1572178E (pt) 2006-09-29
WO2004054557A2 (en) 2004-07-01
US20050032909A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
HK1075403A1 (en) Treatment of mastalgia with 4-hydroxy tamoxifen
WO2004054558A3 (en) Reduction of breast density with 4-hydroxy tamoxifen
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
CZ2006579A3 (cs) Kožní mikroaktivační systém
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2006040688A3 (en) Inhibitors of acetylcholinesterase for treating skin diseases
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
IL166596A0 (en) Salt of morphine-6-glucoronide
WO2009106555A3 (fr) Gel de sucralfate sterilise
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
BRPI0417230A (pt) bactéria produtora da l-treonina pertencente ao gênero escherichia, e, método para produzir l-treonina
DE602004025683D1 (de) Therapeutische zubereitung für autoimmune erkrankungen
HRP20030057B1 (en) Antiseptic for wounds and mucous membranes
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
IL182297A (en) Use of winter savory (satureja montana) or the extracts thereof for the preparation of medicaments for the treatment of the premature ejaculation
HK1103027A1 (en) 4-hydroxy tamoxifen gel formulations
EP1591123A4 (en) USE OF NARINGENINE, NARINGIN AND THEIR SALTS AS EXPERTS IN THE TREATMENT OF COUGH AND COMPOSITIONS THEREOF
WO2003075926A8 (en) Use of proton pump inhibitors for the treatment of airway disorders
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
UA41758A (uk) Спосіб укорінення зимових живців сортової шовковиці
AU2003301174A1 (en) Liposomal analgesic formulation and use
UA38006A (uk) Хондропротективний препарат
UA3134U (uk) Гель глибинної дії на капіляри і обмінні процеси "д. кавілін"

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231216